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Abstract
Long-term treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) down-regulates select protein kinase C (PKC)
isozymes and may differentially affect PKC substrates. We investigated the role of PKC down-regulation on phosphorylation
of two PKC substrates, the 43 kDa growth-associated protein (GAP-43) and the myristoylated alanine-rich C-kinase
substrate (MARCKS) in SK-N-SH human neuroblastoma cells. Cells were treated with 70 nM TPA for 15 min, 17 or 72 h.
Phosphorylation of MARCKS and GAP-43 was elevated throughout 72 h of TPA. The magnitude and peptidic sites of
phosphorylation in GAP-43 and MARCKS were similar after all TPA treatments. GAP-43, but not MARCKS, content was
increased after 17 and 72 h of TPA. The ratio of GAP-43 phosphorylation to content was elevated throughout 17 h but
returned to control by 72 h as content increased. PKC O and K isozyme content was greatly reduced after 72 h of TPA but
membranes retained 23% of PKC activity. Only PKC O translocated to membranes after 15 min TPA. GAP-43 content after
72 h of TPA was increased in subcellular fractions in which significant PKC O isozyme concentration remained. These results
demonstrate that continuous TPA differentially affected phosphorylation of PKC substrate proteins and regulation of PKC
isozyme content in SK-N-SH cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The protein kinase C (PKC) family of serine/threo-
nine protein kinases contains at least eleven isozymes
that are classi¢ed into three or four subgroups (for
reviews see [28,33]). The classical PKC isozymes are
activated by Ca2 and diacylglycerol; the Ca2-inde-
pendent novel PKCs are activated by phospholipid
alone and the Ca2- and diacylglycerol-independent,
atypical PKCs and PKC W are activated by as yet
undetermined mechanisms. The tumor-promoting
phorbol esters, which structurally resemble diacylgly-
cerol, activate classical and novel PKC isozymes but
do so at basal intracellular Ca2 levels ([Ca2]i) [50].
12-O-Tetradecanoylphorbol 13-acetate (TPA) ini-
tially binds to PKC in the cytosol, whereupon the
enzyme translocates to membranes where it can be
proteolytically cleaved [22]. Initial proteolytic cleav-
age may lead to a constitutive, activator-independent
protein kinase [9,49]. Long-term treatment (10^72 h)
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of intact cells with phorbol esters decreases phorbol
ester binding, PKC activity and PKC immunoreac-
tivity to very low levels [28] due to proteolysis of
isozymes by calpain [32] and serine proteases
[12,28]. PKC isozymes that do not bind phorbol es-
ters or diacylglycerol are not down-regulated by per-
sistent phorbol ester treatment [28]. Continuous
TPA, however, selectively down-regulates the PKC
isozymes; those that are most a¡ected depend upon
the cell type [9,22,28]. Long-term treatment of some
cell types with TPA leads to di¡erentiation of the
cells [5,39].
In some cells, there appears to be a dichotomy
between the profound down-regulation of PKC ac-
tivity and the persistent elevation of phosphate con-
tent in a PKC substrate protein. Continuous treat-
ment of human neuroblastoma cells [38] and human
astrocytoma cells [5] with TPA down-regulated the
PKC activity or isozyme content yet phosphorylation
of the prominent PKC substrate, myristoylated ala-
nine-rich C-kinase substrate (MARCKS), remained
enhanced. The MARCKS protein is a ubiquitously
expressed predominantly membrane-associated pro-
tein that has been postulated to play a role in a
number of cellular processes including secretion
and membrane tra⁄cking, cell motility, regulation
of the cell cycle, and transformation (for reviews
see [1,6]). There are at least three phosphorylation
sites for PKC on MARCKS, all contained within a
25 amino acid basic sequence [20]. In a previous
study, we found that treatment of the human neuro-
blastoma cell line, SK-N-SH, with TPA for 72 h led
to a down-regulation of K and O isozymes of PKC
but an enhanced phosphorylation of MARCKS [46].
Another prominent PKC substrate is the 43 kDa
growth-associated protein (GAP-43) (neuromodulin,
B50, F1), a neural-speci¢c protein that is phosphory-
lated by PKC at only one site, serine41 [2,14]. GAP-
43, also predominantly membrane-bound, is thought
to play a role in neuritogenesis, synaptic plasticity
and neurotransmitter release (for reviews see [3,19]).
While it is known that long-term treatment of SH-
SY5Y cells with TPA increases GAP-43 mRNA and
protein expression [23,39], the e¡ect of this treatment
on GAP-43 phosphorylation has not been investi-
gated.
The objective of this study was to examine the
e¡ect of long-term treatment with TPA on phosphor-
ylation state of GAP-43 in SK-N-SH cells and com-
pare it with the apparently constitutive phosphoryla-
tion of MARCKS. Since both are membrane-
associated, acid-soluble, PKC substrate proteins
that may be involved in similar processes such as
cell di¡erentiation, synaptic plasticity and neuro-
transmitter release, it is of interest to examine
whether their phosphorylation is similarly regulated
by continuous TPA. If so, this would imply that the
physiological actions of phosphorylated forms of
these proteins would be prolonged following an ex-
tended activation of PKC, where the actions of other
PKC substrates might be decreased.
2. Materials and methods
2.1. Materials
Cell culture plasticware was from Costar Scienti¢c
(Cambridge, MA). Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM), fetal bovine serum, penicillin/strep-
tomycin solution, TPA, protein A-Sepharose, pep-
statin, leupeptin, phenylmethylsulfonyl £uoride
(PMSF), bovine serum albumin, phosphatidylserine,
diolein, Staphylococcus aureus V8 protease (SAPV8),
5-bromo-4-chloro-3-indoyl phosphate and nitroblue
tetrazolium were purchased from Sigma (St. Louis,
MO). [32P]i-Orthophosphoric acid in HCl-free water
(8150^9120 Ci/mmol) was purchased from DuPont
NEN (Boston, MA). 4K-TPA was purchased from
LC Laboratories (Woburn, MA). Ro31-8220 was
purchased from Calbiochem (San Diego, CA). Nitro-
cellulose transfer membranes were from standard
suppliers. All other chemicals were of analytical
grade.
2.2. Cell culture
SK-N-SH human neuroblastoma cells were seeded,
grown and harvested as described [29]. Cells were
treated with 70 nM TPA in culture medium as de-
scribed previously [46]. Although the SK-N-SH cell
line has been reported to exhibit both neuroblast and
epithelial phenotypes [43], under our culture condi-
tions, i.e. relatively prolonged culture at low initial
subculture densities, only the neuroblastoma pheno-
type is found [44].
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2.3. Labeling of cells with [32P]i and perchloric acid
(PCA) extraction
Incubation of cells with [32P]i and isolation of the
PCA-soluble fraction ware performed as described
[46]. Brie£y, monolayers were washed twice and in-
cubated with 2 ml of phosphate- and serum-free
DMEM for 1 h at 37‡C. Medium was replaced
with 0.5 mCi [32P]i in 1 ml phosphate-free DMEM
per well and incubated for two more hours. For a
15 min treatment, TPA or vehicle was added directly
to the medium as part of the 2 h labeling period. The
reaction was stopped by aspirating the medium and
washing the monolayers twice with cold Tris-bu¡ered
saline (TBS). After TBS removal, cells were extracted
with 150^300 Wl of 2.5% perchloric-acid (PCA) con-
taining 150 mM NaCl and 1% Triton X-100 [17].
Extracts were sonicated for 15 min in a water bath
sonicator, centrifuged 10 min at 15 000Ug at 4‡C,
then neutralized with 2 M NaOH. Protein concen-
tration of supernatants (PCA-soluble fraction) was
measured using the Pierce BCA protein assay with
bovine serum albumin as a standard.
2.4. SDS-PAGE and autoradiography
5 Wg of neutralized PCA-soluble protein per treat-
ment was diluted in SDS-sample bu¡er [25], heated
5 min at 100‡C and resolved by SDS-PAGE on
12U14 cm (Hoefer Scienti¢c, San Francisco, CA)
gels at 7 or 7.5% polyacrylamide. Gels were soaked
in 20% methanol, 5% acetic acid for 30 min, dried on
a Bio-Rad gel dryer for 1.5 h at 80‡C and exposed to
Kodak X-Omat AR ¢lm for 4^24 h. Quantitation
using Imagequant software (Molecular Dynamics,
Sunnyvale CA) was done after exposing the gels to
a phosphor screen for 6^16 h.
2.5. Immunoprecipitation of MARCKS and GAP-43
from 32Pi-labeled cells
Immunoprecipitation of MARCKS from 32Pi-la-
beled cells was performed as described previously
[46], using 10 Wg of neutralized PCA-soluble protein
per condition. GAP-43 was immunoprecipitated ac-
cording to the method of Chapman et al. [11] with
the following changes. The bu¡er used throughout
the experiment was TEG bu¡er (10 mM TES, pH
7.6, 50 mM NaCl, 4 mM EDTA, 10% glycerol).
Neutralized PCA-soluble protein (5 Wg) from 32Pi-
labeled cells was precleared with 1 Wg non-immune
mouse IgG and 50 Wl of a 20% slurry of protein
G-Sepharose in TEG bu¡er (total assay volume
350 Wl) for 1 h at 4‡C with rotation. Samples were
centrifuged at 15 000Ug for 5 min. Supernatants
were removed and added to tubes containing 1 Wg
monoclonal anti-GAP-43 (91E12 from Boehringer
Mannheim Biochemicals, Indianapolis, IN) and
were incubated overnight at 4‡C with rotation. A
20% slurry (50 Wl) of protein A-Sepharose was added
to each tube and incubation was continued as above
for 2 h. The samples were centrifuged as above, the
supernatants removed and the immune pellets
washed three times with 500 Wl of TEG bu¡er per
wash. The ¢nal pellets were resuspended in SDS-
sample bu¡er and heated 5 min at 100‡C. Samples
were resolved by electrophoresis on 7% polyacryl-
amide gels, dried and exposed to ¢lm.
2.6. GAP-43 and MARCKS immunoblotting
All incubations were performed at room temper-
ature for 1 h unless otherwise noted. For GAP-43,
neutralized PCA-soluble extracts (15^40 Wg) were
prepared for SDS-PAGE and resolved by electropho-
resis as above. Proteins were transferred to nitrocel-
lulose membranes and blocked with 2% non-fat dry
milk in TBS containing 0.1% Tween-20 (TTBS).
Membranes were incubated with 0.1 Wg/ml anti-
GAP-43 clone 91E12 in blocking bu¡er, washed
three times with TTBS, and then incubated with a
1:7500 dilution of goat anti-mouse IgG alkaline
phosphatase conjugate (Promega, Madison, WI) in
blocking bu¡er and washed again. Immunoreactive
proteins were detected with 5-bromo-4-chloro-3-in-
doyl phosphate and nitroblue tetrazolium as enzyme
substrates. Blots were scanned using a Hewlett-Pack-
ard ScanJet IIc and density of the bands determined
using Imagequant software as described previously.
MARCKS immunoblotting was similarly performed
except that the blocking bu¡er was 5% non-fat dry
milk in TTBS. The primary antibody was polyclonal
rabbit anti-human MARCKS (Dr. David Byers, At-
lantic Research Center, Nova Scotia, Canada) di-
luted 1:2000 in blocking bu¡er. The secondary anti-
body was goat anti-rabbit IgG alkaline phosphatase
BBAMCR 14454 29-3-99
A.M. Goldsmith, M.E. Gnegy / Biochimica et Biophysica Acta 1449 (1999) 269^283 271
conjugate (Life Technologies, Grand Island, NY) di-
luted 1:10 000 in blocking bu¡er.
2.7. HPLC analysis of MARCKS tryptic
phosphopeptides
PCA-soluble protein (15 Wg) from 32Pi-labeled cells
which had been treated with or without TPA was
separated by 7% SDS-PAGE and gels were dried
and exposed to ¢lm. The bands corresponding to
MARCKS were excised and prepared for HPLC ac-
cording to Blackshear et al. [7] with minor modi¢ca-
tions. Brie£y, the excised gel pieces were rehydrated
in 10 mM Tris-HCl, pH 7.4, 5 mM MgCl2 for 5^
10 min with several bu¡er changes. Each piece was
then cut into smaller pieces with a razor blade, added
to 2 ml of the same bu¡er containing 500 Wg of
trypsin (N-tosyl-L-phenylalanine chloromethyl ke-
tone-treated) (Sigma, St. Louis, MO) and incubated
for 24 h at 37‡C with rotation. The samples were
centrifuged, washed once with 0.5 ml of Tris-MgCl2
bu¡er and the supernatants combined and lyophi-
lized. Lyophilized samples were dissolved in a small
volume of 0.01% (v/v) tri£uoroacetic acid, and
separated on a 2.1 mmU15 cm C4 reverse phase
high performance liquid chromatography column
(Vydac silica 5 Wm, Phenomenex, Torrance CA)
using a gradient of 0^60% (v/v) acetonitrile in
0.1% (v/v) tri£uoroacetic acid at a £ow rate of
0.8 ml/min. Fractions were collected every 30 s and
counted on a Beckman Model LS5800 scintillation
counter.
2.8. SAPV8 protease digestion of 32P-labeled GAP-43
GAP-43 was immunoprecipitated as above and
resolved by electrophoresis on a 7% polyacrylamide
gel. After electrophoresis, gels were exposed to ¢lm
for 1^2 h. The band corresponding to [32P]-GAP-43
was excised and put in 80 Wl of SDS-sample bu¡er. A
20 Wl volume of SAPV8 in SDS-sample bu¡er was
added for a ¢nal amount of 3.3 ng of enzyme per
sample. The gel pieces and bu¡er were placed into
the bottom of wells of a 15% SDS gel which had a
4% stacking gel of at least 2 cm in length [13].
Electrophoresis was performed overnight at 50 V.
Gels were dried and exposed to ¢lm as described
earlier.
2.9. Protein kinase C isozyme immunoblotting
100 000Ug supernatant and pellet fractions were
prepared after homogenizing cells in a bu¡er con-
taining 0.32 M sucrose, 40 mM Tris-HCl, pH 7.4,
1 WM leupeptin, 1 WM pepstatin and 1 mM phenyl-
methylsulfonyl £uoride. The fractions were resolved
by electrophoresis on 7.5% SDS-PAGE gels and
transferred to nitrocellulose membranes. Membranes
were blocked with 2% non-fat dry milk in TTBS
(PKC L was blocked with 3% milk in TTBS) and
incubated in blocking bu¡er with monoclonal mouse
anti-PKC K (1:500 dilution) (a generous gift from
Karen L. Leach, Upjohn Laboratories, Kalamazoo,
MI), a⁄nity puri¢ed rabbit anti-PKC L (1:500 dilu-
tion in TTBS+1% milk) (Life Technologies, Grand
Island, NY), or a⁄nity puri¢ed rabbit anti-PKC O or
j (1:1250 or 1:1000 dilution in blocking bu¡er, re-
spectively) (Life Technologies). After three washes
with TTBS, membranes were incubated either with
goat anti-mouse IgG alkaline phosphatase conjugate
(1:7500 in blocking bu¡er; Promega) for PKC K, or
goat anti-rabbit IgG alkaline phosphatase (Life
Technologies) for PKC O and j (1:10 000 in blocking
bu¡er) and PKC L (1:10 000 in TTBS+0.5% non-fat
dry milk). Blots were washed and immunoreactive
proteins detected with 5-bromo-4-chloro-3-indoyl
phosphate and nitroblue tetrazolium.
2.10. Measurement of PKC activity
Cells were grown and treated in 35 mm cell culture
plates with TPA for the indicated times. The medium
was removed by aspiration and the monolayers were
washed twice with cold TBS. The TBS was removed
and 200 Wl of cold lysis bu¡er (10 mM Tris-HCl, pH
7.4, 10 mM MgCl2, 150 mM NaCl, 1 mM L-mercap-
toethanol, 10 WM leupeptin, 10 WM pepstatin and
1 mM PMSF) was added to each well. Cells were
incubated for 2 min at room temperature prior to
collection with a cell scraper and sonication for
10 s. Lysates were then centrifuged at 100 000Ug
for 60 min. Pellets were brought to 1% Triton
X-100 in the above bu¡er and incubated at least
30 min on ice prior to a 10-fold dilution into the
assay. PKC activity was measured in an assay
(50 Wl) containing 20 mM Tris-HCl, pH 7.5, 5 mM
magnesium acetate, 50 WM CaCl2, 20 WM ATP
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(0.3 WCi [32P]-ATP/assay), 25 WM myelin basic
protein4ÿ14 (Upstate Biotechnology, Lake Placid,
NY), 80 Wg/ml phosphatidylserine, 10 Wg diolein
with 2 Wg sample protein. Samples were incubated
4 min at 30‡C. The reaction was stopped by spotting
a 30 Wl aliquot onto P-81 ¢lter paper (Whatman,
Maidstone, UK) and washing in 75 mM H3PO4 as
described [54]. All radioactivity was measured using
L-scintillation counting on a Beckman LS5800.
2.11. Subcellular fractionation of SK-N-SH cells
Cells were treated with TPA and harvested as de-
scribed above. All subsequent steps were performed
at 4‡C. Cells were homogenized in 40 mM Tris-HCl,
pH 7.4, 0.32 M sucrose (Tris-sucrose bu¡er) with
10 strokes of a glass-te£on homogenizer. The homo-
genate was centrifuged at 1000Ug for 10 min. The
pellet was resuspended in the bu¡er, recentrifuged
and the resultant pellet (P1) was resuspended in
Tris-sucrose bu¡er. The 1000Ug supernatants were
combined, centrifuged at 10 000Ug for 20 min and
the resultant pellet (P2) was resuspended in Tris-su-
crose bu¡er. The 10 000Ug supernatant was centri-
fuged at 100 000Ug for 60 min to yield a 100 000Ug
pellet (P3), which was resuspended in Tris-sucrose
bu¡er, and a 100 000Ug supernatant (S3). Samples
were used immediately or frozen in liquid nitrogen
and stored at 370‡C until used for immunoblotting.
3. Results
3.1. E¡ect of 17 or 72 h treatment with TPA on
phosphorylation of GAP-43 and MARCKS in
SK-N-SH cells
Although our focus is directed to the phosphory-
lation of GAP-43, we initially investigated the incor-
poration of [32P] into PCA-soluble extracts of SK-N-
SH cells to examine both MARCKS and GAP-43
phosphorylation, and to determine whether other
PCA-soluble proteins were a¡ected by this treatment.
Cells were treated with vehicle or 70 nM TPA for
17 or 72 h after which 32P-incorporation into pro-
teins in PCA-soluble extracts was examined. Follow-
ing pretreatment, the cells were challenged with
70 nM TPA for 15 min. As shown in Fig. 1, only
bands migrating at 86 (p86) and 55 (p55) kDa re-
sponded to 15 min of TPA in the vehicle-treated
cells, suggesting that they could be PKC substrates.
There also appeared to be a protein migrating near
46 kDa that responded to TPA but we were unable
to successfully separate out the apparent PKC sub-
strate even when a di¡erent percentage of polyacryl-
amide was used. The phosphate content of p86 and
p55 was increased after cells were treated for 17 and
72 h with 70 nM TPA (Fig. 1). There was no further
response to a 15 min incubation with 70 nM TPA.
The level of 32P-incorporation into these bands after
17 and 72 h of TPA was the same as that attained
after 15 min of 70 nM TPA (Fig. 1 and Table 1).
Long-term treatment with the inactive phorbol ester
4K-TPA (70 nM) did not elevate p86 or p55 phos-
phate content at 17 or 72 h (data not shown). Sub-
sequent treatment of 4K-TPA-treated cells with
70 nM of the active form of TPA (4L-TPA) induced
Fig. 1. E¡ect of 17 or 72 h treatment with 70 nM TPA on
phosphorylation of PCA-soluble proteins in SK-N-SH cells.
Cells were treated with 0.1% DMSO vehicle (V) or 70 nM TPA
for 17 or 72 h in culture. Cells were labeled with [32P]i for 2 h,
treated with 70 nM TPA or 0.1% DMSO vehicle (Ctrl) for
15 min at 37‡C and PCA-soluble extracts prepared as described
in Section 2. 5 Wg/lane of PCA-soluble protein was separated
by 7% SDS-PAGE; gels were dried and exposed to ¢lm. Molec-
ular weight standards (kDa) are indicated to the left.
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increased [32P]-incorporation into both p86 and p55
(data not shown).
3.2. Identi¢cation of GAP-43and MARCKS in the
PCA-soluble fraction
We identi¢ed p86 and p55 as MARCKS and
GAP-43, respectively, by immunoprecipitating the
proteins from the PCA-soluble fraction of 32P-la-
beled SK-N-SH cells. Previously, we immunoprecipi-
tated 32P-labeled MARCKS from 17 and 72 h TPA-
treated SK-N-SH cells [46]. To examine basal phos-
phorylation in untreated cells, the 86 kDa phospho-
protein was immunoprecipitated from both TPA-
treated and untreated cells with an antiserum to
MARCKS (Fig. 2A). A protein migrating at 55 kDa
was immunoprecipitated with a monoclonal antibody
to GAP-43 (Fig. 2B). MARCKS contained a basal
level of [32P] even in control unstimulated cells but
[32P]-GAP-43 was detected only in TPA-treated cells
(Fig. 2B). Only upon long exposure (8^10 days) of
the gel to ¢lm could we detect [32P]-GAP-43 from
untreated cells (see Fig. 5 below). Phosphorylated
and non-phosphorylated GAP-43 were immunopre-
cipitated equally well by the antibody.
3.3. E¡ect of 17 or 72 h treatment with TPA on
content of GAP-43 and MARCKS in SK-N-SH
cells
We examined the e¡ect of long-term TPA on
MARCKS and GAP-43 content by immunoblotting
PCA-soluble protein from TPA-treated and un-
treated cells. MARCKS content did not signi¢cantly
change in response to any length of treatment with
Fig. 2. Identi¢cation of (A) MARCKS and (B) GAP-43 in the
PCA-soluble fraction. 32Pi-Labeled SK-N-SH cells were un-
treated (3) or treated (+) with 70 nM TPA for 15 min and
then (A) 10 Wg of PCA-soluble protein was incubated with a
1:100 dilution of control rabbit serum (serum) or antiserum to
MARCKS (Ab) overnight and immune complexes precipitated
with protein A-Sepharose as described in Section 2. Immuno-
precipitated proteins were separated by SDS-PAGE (8.75%
acrylamide), gels were dried and exposed to ¢lm. (B) 5 Wg of
precleared PCA-soluble protein was incubated with 1 Wg GAP-
43 overnight and immune complexes precipitated with protein
G-Sepharose. Immunoprecipitated protein (IP) or PCA-soluble
protein (PCA) was separated by SDS-PAGE (7% acrylamide)
and gels were dried and exposed to ¢lm. Molecular weight
standards (kDa) are indicated.
Table 1
Ratio of GAP-43 phosphorylation GAP-43 content in long-term TPA-treated SK-N-SH cells
% Control
TPA treatment Content Phosphorylation Phosphorylation/content
Control 100 100 1
15 min 108 þ 5 384 þ 60** 3.56
17 h 245 þ 16* 635 þ 80** 2.59
72 h 371 þ 39* 565 þ 93** 1.59
GAP-43 content and phosphorylation values were determined by densitometry of immunoblots and autoradiographs, respectively, as
described in Section 2. Results are expressed as the percent of control þ S.E.M. from three di¡erent experiments. Values are signi¢-
cantly di¡erent from 100% at *P6 0.005 and **P6 0.05.
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TPA (Fig. 3A) showing that the level of phosphate
incorporation into MARCKS remained elevated
throughout the 17 and 72 h of TPA treatment. On
the other hand, GAP-43 content increased in re-
sponse to both 17 and 72 h of TPA (Fig. 3B). The
GAP-43 content increased by 2.5- and 3.7-fold in
17 and 72 h TPA-treated cells, respectively, as com-
pared to control, untreated cells (Table 1). The ratio
of GAP-43 phosphate levels to GAP-43 content de-
creased with increasing length of incubation with
TPA (Table 1) but was signi¢cantly elevated over
control levels at both 15 min and 17 h of TPA treat-
ment.
3.4. Identi¢cation of phosphorylation sites on GAP-43
and MARCKS
We investigated whether the elevated phosphate
labeling of GAP-43 during the 17 and 72 h of TPA
treatment was on a peptide fragment containing the
PKC site. Digestion of GAP-43 with SAPV8 produ-
ces at least three well-characterized peptides. PKC
phosphorylates GAP-43 at a single amino acid,
serine41. The major peptides from SAPV8 digestion
migrate on SDS-PAGE at approximately 28 kDa
(amino acids 1^132, for the rat protein), 21 kDa
(amino acids 133^226) and 15 kDa (amino acids 1^
65, 66^132) [14]. The human protein is 12 amino
acids longer, 9 of which are just amino-terminal to
amino acid 132 [24]. Immunoprecipitated 32P-labeled
GAP-43, prepared from cells treated with or without
70 nM TPA for 15 min, 17 and 72 h, was digested
with SAPV8 during electrophoresis on a 15% poly-
acrylamide gel [13]. After treatment with SAPV8, the
pattern of phosphopeptides produced was similar for
all three TPA treatments (Fig. 4). In addition to the
45 kDa undigested GAP-43, SAPV8 produced pep-
tides of approximately 28, 21 and 15 kDa. The con-
trol sample did not show the presence of a 15 kDa
fragment, however, and contained very low levels of
radioactivity.
It has previously been demonstrated that the phos-
phorylation sites on MARCKS protein are virtually
identical after either 16 h or 10 min exposure to a
high dose (16 WM) of TPA [5]. We used a lower dose
of TPA (70 nM) but treated cells for longer times
(72 h). Therefore, we examined whether the phos-
Fig. 4. Staphylococcus aureus V8 protease (SAPV8) digestion of
[32P]-GAP-43 from SK-N-SH cells untreated or treated with
TPA for 15 min, 17 or 72 h. Cells were treated with vehicle
(0.1% DMSO) or 70 nM TPA for 17 or 72 h in culture, and la-
beled with [32P]i for 2 h. Vehicle-treated cells were left un-
treated (Ctrl) or treated with 70 nM TPA for 15 min at 37‡C,
and PCA-soluble protein was prepared for all conditions as de-
scribed in Section 2. 15 Wg/lane of PCA-soluble protein was im-
munoprecipitated with monoclonal anti-GAP-43, and immuno-
precipitated protein was separated by 7% SDS-PAGE. Wet gels
were wrapped in plastic wrap, exposed to ¢lm, and the bands
corresponding to GAP-43 were cut out of the gel. Gel pieces
were resuspended in SDS-sample bu¡er and left untreated or
digested with 3.3 ng SAPV8 per gel piece during electrophoresis
on a 4% stacking and 15% separating gel [13]. Gels were dried
and exposed to ¢lm. Molecular weights (kDa) of the 32P-labeled
bands are indicated to the right.
Fig. 3. E¡ect of 17 or 72 h treatment with 70 nM TPA on (A)
MARCKS and (B) GAP-43 content in SK-N-SH cells. Cells
were treated with 0.1% DMSO vehicle (V) or 70 nM TPA for
17 or 72 h in culture. Cells were harvested, treated with 70 nM
TPA or 0.1% DMSO vehicle (Ctrl) for 15 min at 37‡C and
PCA-soluble extracts prepared as described in Section 2. 50 Wg/
lane (MARCKS) or 25 Wg/lane (GAP-43) of PCA-soluble pro-
tein was separated by 7.5% SDS-PAGE, and proteins were
transferred to nitrocellulose membranes. Membranes were
probed with (A) polyclonal anti-human MARCKS, or (B)
monoclonal anti-mouse GAP-43 as described.
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phorylation sites of MARCKS induced by long-term
TPA treatment of SK-N-SH cells were the same as
those induced by short-term (15 min) TPA treat-
ment. PKC phosphorylates MARCKS at 3 serines,
all within a 25-amino acid region on MARCKS [20]
but other sites are phosphorylated by other kinases
[51,53]. Tryptic phosphopeptides of MARCKS, la-
beled with [32P]i in cells treated with TPA for 15
min, 17 or 72 h, were subjected to reverse phase
HPLC. There were peaks of radioactivity at fraction
numbers 5, 28, 40 and 50 for all TPA-treated samples
(Fig. 5). Compared to the control, vehicle-treated
sample, peaks at fractions 40 and 50 were increased
in all TPA-treated samples. There was signi¢cant
basal incorporation of [32P] into MARCKS in un-
treated cells.
3.5. E¡ect of short- and long-term TPA treatment on
PKC isozyme content and activity in SK-N-SH
cells
Since the phosphorylation of GAP-43 was main-
tained for 17 h of TPA treatment and MARCKS for
72 h, we analyzed the responsiveness of PKC iso-
zyme content and general activity to acute and
long-term TPA. We had found that long-term TPA
in SK-N-SH cells down-regulated the K and O iso-
zymes of PKC [46] but did not examine acute e¡ects
of TPA. Examination of the vehicle-treated cells in
Fig. 6 reveals that only PKC O was translocated from
the supernatant to the pellet in response to 15 min of
TPA even though both the K and L isozymes of PKC
are also sensitive to TPA [28]. The content of both
Fig. 5. Identi¢cation of phosphorylation sites on MARCKS from SK-N-SH cells untreated or treated with TPA for 15 min, 17 or
72 h. Cells were treated with 0.1% DMSO vehicle or 70 nM TPA for 17 or 72 h in culture and labeled with [32P]i for 2 h. The
vehicle-treated cells were left untreated (Control) or treated with 70 nM TPA for 15 min at 37‡C. PCA-soluble protein was prepared
as described in Section 2. 15 Wg/lane of PCA-soluble protein was separated by 7% SDS-PAGE, gels were dried, exposed to ¢lm and
the bands corresponding to MARCKS cut out of the gel. Gel pieces were rehydrated, digested with trypsin, lyophilized, and subjected
to reverse phase HPLC as described. Fractions were collected and radioactivity measured by liquid scintillation counting. Results are
expressed as the percentage of total cpm multiplied by 100 for each sample.
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PKC K and O in the supernatant was greatly reduced
after 17 or 72 h of TPA. However, PKC K in the
membrane fraction appeared to be more sensitive to
continuous TPA than was membrane-associated
PKC O (Fig. 6C). The membrane fraction of PKC
K showed an obvious doublet after 17 and 72 h,
perhaps due to a change in phosphorylation state
of the enzyme (Fig. 6A). PKC O migrated as a dis-
tinct doublet in both supernatant and membrane
fractions. The blots in Fig. 6B,D distinctly demon-
Fig. 6. Immunoblot analysis of PKC isozymes from SK-N-SH cells untreated or treated with TPA for 15 min, 17 or 72 h. Cells were
treated with 0.1% DMSO vehicle (V) or 70 nM TPA for 17 or 72 h in culture. Cells were harvested, treated with 70 nM TPA or
0.1% DMSO vehicle (Ctrl) for 15 min at 37‡C and 100 000Ug cytosolic and membrane fractions prepared as described in Section 2.
Either 20 Wg (cytosol) or 30 Wg (membrane) of protein was separated by 7.5% SDS-PAGE, and proteins were transferred to nitrocellu-
lose membranes. Blots were probed with (A) monoclonal anti-PKC K, or a⁄nity puri¢ed antibodies to (B) PKC L, (C) O or (D) j as
described.
Table 2
PKC activity in supernatant and membrane fractions from untreated SK-N-SH and cells treated for various times with TPA
TPA treatment PKC activity
Supernatant Membrane
pmol/min/mg protein % Control pmol/min/mg protein % Control
None 1055 þ 69 1783 þ 53
15 min 681 þ 68* 65 2538 þ 145** 142
17 h 119 þ 27* 11 671 þ 31** 38
72 h 70 þ 55* 6.6 414 þ 53** 23
SK-NH-SH cells treated with 70 nM TPA for the times indicated. Cells were homogenized and 100 000Ug supernatant and membrane
fractions were fractions were prepared and assayed for PKC activity as described in Section 2. Results are expressed as the mean þ
S.E.M. for three separate experiments.
*For all supernatant values, P6 0.0001 by ANOVA. In Tukey-Kramer post-test analysis, P6 0.01 for 15 min in comparison to all
other values; P6 0.001 for 17 and 72 h as compared to control.
**For all membrane values, P6 0.0001 by ANOVA. In Tukey-Kramer post-test analysis, P6 0.001 for all values as compared to con-
trol and for 15 min as compared to control, 17 and 72 h.
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strate that neither acute nor continuous TPA altered
PKC L or PKC j. A subsequent 15 min incubation
with 70 nM TPA did not alter the localization of
PKC isozymes in long-term TPA-treated cells.
PKC activity assays were performed on 100 000Ug
cytosol and membrane fractions from the treated
cells using MBP4ÿ14 as a substrate. The data in
Table 2 demonstrate that the 15 min TPA treatment
elicited the expected increase in PKC activity in the
membrane fraction and a decrease in the supernatant
fraction. After 17 or 72 h of 70 nM TPA, the PKC
activity in the supernatant fraction was nearly abol-
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ished. The PKC activity in the membranes was also
greatly reduced but at least 23% of the control activ-
ity was present after 72 h of TPA.
3.6. E¡ect of long-term TPA treatment on the
subcellular distribution of GAP-43, PKC K and
PKC O
Although it appeared that residual PKC activity in
membranes could maintain elevated phosphorylation
of MARCKS, phosphorylation of GAP-43 was not
elevated concomitant with the increase in content.
Two possibilities are that either the entire GAP-43
pool becomes evenly phosphorylated or the newly-
synthesized GAP-43 was not being phosphorylated.
We examined whether the subcellular distribution of
GAP-43 and select PKC isozymes would be parallel
or divergent after short- and long-term TPA. Subcel-
lular fractions from vehicle- or TPA-treated cells
were immunoblotted for GAP-43, PKC K and PKC
O. The data from the immunoblots (Fig. 7A) of three
separate experiments were quanti¢ed and are shown
in Fig. 7B. The subcellular distribution of each pro-
tein and its response to TPA was unique. GAP-43
was highly concentrated in the P2 fraction in control
cells with very low concentrations in the P3 and S3
fractions and its distribution was not altered by 15
min of 70 nM TPA. After 72 h of TPA, however,
GAP-43 content was signi¢cantly increased in both
the P1 and P2 fractions. PKC O, which was most
concentrated in the S3 fraction in untreated cells,
translocated from the P3 and S3 fractions to the P2
fraction after 15 min of TPA. After 72 h of TPA, the
PKC O in P3 and S3 fractions remained low but the
concentration in the P1 and P2 fractions were 60 and
36%, respectively, of those given 15 min of TPA.
Although PKC K showed no redistribution after 15
min of TPA its content was evenly reduced in all
fractions after 72 h of TPA.
4. Discussion
Continuous treatment with TPA generally results
in decreases in content of select PKC isozymes, PKC
activity, phosphorylation of substrate proteins and
physiological response to PKC activation [28]. We
and others, however, found that phosphorylation of
MARCKS is maintained during prolonged TPA
treatment in SK-N-SH cells [46] and the subclone
SH-SY5Y [38] and 1321 human astrocytoma cells
[5]. In this study, we examined whether phosphory-
lation of another prominent PKC substrate, GAP-43,
would be regulated similarly to MARCKS. This is
the ¢rst report to investigate the phosphorylation of
GAP-43 as a result of persistent PKC activation.
Enhanced phosphate levels in GAP-43 were main-
tained for only 17 h due to increased synthesis of
the protein while the enhanced labeling of MARCKS
was maintained throughout 72 h of TPA treatment.
These results demonstrate that prolonged activation
of PKC need not result in a generalized reduction in
phosphorylation of PKC substrates and that selective
regulation of substrate phosphorylation can occur
even with a general activator such as TPA. The
fact that the phosphate to protein ratio of GAP-43
Fig. 7. Subcellular fractionation and immunoblot analysis of GAP-43, PKC K and PKC O from SK-N-SH cells. Cells were treated
with 0.1% DMSO vehicle or 70 nM TPA for 72 h in culture or for 15 min just prior to harvest. All cells were harvested and homo-
genized in Tris-sucrose bu¡er as described in Section 2. Cells were fractionated by centrifugation at 1000Ug, then 10 000Ug and ¢-
nally 100 000Ug to yield P1, P2, and P3 and S3 fractions, respectively. 30 Wg of protein was separated by 10% SDS-PAGE, trans-
ferred to nitrocellulose membranes and immunoblotted with antibodies to GAP-43, PKC K or PKC O. (A) Representative
immunoblots. (B) Quanti¢cation of immunoblots for subcellular fractions from control cells (striped), cells treated with 70 nM TPA
for 15 min (stippled) and cells treated for 72 h (solid). Immunoblots were scanned using a Hewlett-Packard ScanJet IIc and density of
the bands determined using Imagequant software. Results are given as optical density (O.D.) þ S.E.M. for three separate experiments.
Statistical signi¢cance for changes within a speci¢c fraction was determined by a one-way ANOVA with Tukey-Kramer post-test anal-
ysis. *Denotes a level of signi¢cant di¡erence. For GAP-43: P1, ANOVA P6 0.005, 72 h values di¡er from Con and 15 min at
P6 0.01; P2, ANOVA, P6 0.02, 72 h values di¡er from Con and 15 min at P6 0.05. For PKC O : P1, ANOVA P6 0.01, 72 h values
di¡er from Con at P6 0.05, 72 h values di¡er from 15 min at P6 0.01; P2, ANOVA, P6 0.005, 15 min values di¡er from Con at
P6 0.05; 72 h values di¡er from 15 min at P6 0.01; P3, ANOVA P6 0.02, Con and 15 min vs. 72 h, P6 0.05; S3 ANOVA,
P6 0.0001, Con and 15 min vs. 72 h, P6 0.001. For PKC K ; all values at 72 h are signi¢cantly di¡erent from Con and 15 min at
P6 0.01.
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returned to control levels at 72 h suggests that either
the newly-synthesized GAP-43 is phosphorylated in
response to the continuous TPA or that GAP-43 at a
select location is retaining high phosphate levels.
Continuous TPA treatment can also lead to cellular
di¡erentiation [5,39]. The enhanced phosphorylation
of MARCKS after TPA is a result of the continued
presence of TPA rather than cell di¡erentiation per
se [39] because MARCKS was not continuously
phosphorylated upon di¡erentiation of the cells
with retinoic acid [46].
Long-term treatment with TPA also leads to stable
elevated phosphate incorporation into pp60src and
the high molecular weight subunit of neuro¢lament
in SH-SY5Y cells [4,26] and epidermal growth factor
receptor in human diploid ¢broblasts [15]. We now
report that phosphorylation of GAP-43 is also en-
hanced after 17 h of TPA. The proteins reported
thus far to demonstrate enhanced 32P-labeling after
prolonged TPA are membrane- and/or cytoskeleton-
bound proteins. PKC-dependent phosphorylation of
GAP-43 has been shown to be important for Ca2-
dependent neurotransmitter release [16], cell growth
and learning [47] and growth cone extension [18].
Phosphorylation of GAP-43 at the PKC substrate
site, ser41 is important for ¢broblast growth factor-
induced stimulation of neurite outgrowth in neurites
and growth cones [30]. Prolonged phosphorylation of
either GAP-43 or MARCKS could have signi¢cant
e¡ects on the cell cytoskeleton resulting in altered
cell function and motility.
The enhanced 32P-labeling in MARCKS and
GAP-43 could be due to constitutively active PKC.
Administration of fresh TPA after 72 h elicited
no further enhancement of phosphorylation of
MARCKS suggesting that the remaining PKC activ-
ity could be constitutive. Our assays showed that as
much as 23% of PKC activity and signi¢cant
amounts of PKC isozymes remain in membranes
after 17 and 72 h of TPA. In support of the concept
of a persistently activated PKC, activation of PKC
LII [8] and O [42] isozymes by phorbol esters resulted
in their binding to the actin cytoskeleton with persis-
tent activation. Prekeris et al. [42] demonstrated that
the binding of activated PKC O to actin in the cyto-
skeleton of hippocampal synaptosomes elicited pro-
longed activation of an 80 kDa PKC substrate even
after the TPA stimulus was washed out. Both
MARCKS [10,21] and GAP-43 [35] can be phos-
phorylated in vitro by several of the PKC isozymes
including LII and O isozymes. The pattern of expres-
sion of GAP-43 and PKCLII in vivo are highly sim-
ilar in nerve endings in the hippocampus [47] and in
growth cones [18].
The isozyme that could be contributing to the en-
hanced phosphorylating activity after TPA treatment
in SK-N-SH cells is unknown, but of the PKC iso-
zymes we examined, PKC O was the most responsive
to short-term TPA stimulation. TPA induced a pro-
nounced redistribution of the O isozyme from the
soluble and P3 fractions to the P2 fraction and there
was a signi¢cant amount of the O isozyme remaining
in the membrane fractions after 17 and 72 h of TPA.
We and others [23,26] found that continuous TPA
had a greater e¡ect in down-regulating the K isozyme
of PKC as compared to the O isozyme in SK-N-SH
and SH-SY5Y cells. Based on the subcellular fractio-
nation immunoblots, the PKC O concentration and
total content at 72 h of TPA represented 36 and 72%,
respectively, of the values attained at 15 min of TPA.
The L isoform did not change in response to short-
term TPA, but neither was it down-regulated in re-
sponse to continuous TPA. Therefore it, too, could
be contributing to the enhanced phosphorylation of
MARCKS and GAP-43. One cannot discount, how-
ever, that altered phosphatase activity is playing a
role in our reported increase in 32P-labeling of
GAP-43 and MARCKS.
Enhanced phosphorylation of MARCKS in re-
sponse to continuous TPA is not a general phenom-
enon and has been most often reported in human
cells. Prolonged TPA decreased MARCKS content
in human megakaryoblastic leukemia cells [31], im-
mortalized rat hippocampal cell line HN33 [52] and
mouse Swiss 3T3 ¢broblasts [27]. Similarly, down-
regulation of PKC activity in rat oligodendrocytes
resulted in a total inhibition of GAP-43 phosphory-
lation [17]. A factor that may contribute to the en-
hanced phosphorylation and apparent retention of
some membrane PKC activity is the metabolism of
TPA which may depend upon both the species and
the cell type. Human ¢broblasts were largely unable
to metabolize TPA while mouse ¢broblasts readily
metabolized the phorbol ester. On the other hand,
human hepatoma cells did metabolize TPA [34]. If
SK-N-SH and SH-SY5Y cells do not metabolize
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TPA it could remain active for long periods of in-
cubation.
In contrast to MARCKS, enhanced phosphoryla-
tion of GAP-43 was maintained only for 17 h.
Although labeling of the GAP-43 was still enhanced
at 72 h compared to control, the content of GAP-43
was similarly increased. Perrone-Bizzozero et al. [40]
have shown that PKC activation stabilized the
mRNA of GAP-43 in PC-12 cells, an action which
may also be operative in SK-N-SH cells. At 72 h, the
ratio of phosphorylated GAP-43 to total GAP-43
was at control levels. It is unclear whether newly-
synthesized GAP-43 is becoming phosphorylated or
whether the older phosphorylated pool of GAP-43
remains stable and the newly synthesized pool of
GAP-43 does not have increased phosphate content.
However, because the increase in GAP-43 content is
highest in the P1 and P2 fractions, and there is sig-
ni¢cant PKC remaining in those fractions, the newly-
synthesized GAP-43 could be phosphorylated by re-
maining PKC activity.
The investigation of the labeled peptides of the
digested proteins suggested that PKC activation
was responsible, either directly or indirectly, for the
enhanced phosphorylation of both GAP-43 and
MARCKS. For GAP-43, the pattern of 32P-labeled
peptides produced by SAPV8 digestion (on a 15%
gel) was nearly identical for all three lengths of
TPA treatment. These results show the presence of
32P-labeled peptides at 28, 21 and 15 kDa, as well as
the 45 kDa undigested protein. The PKC site at
serine41 is contained in the 28 kDa fragment and
one of the 15 kDa fragments. Phosphorylation of
GAP-43 and MARCKS induced by a 15 min of
TPA was completely inhibited by the selective PKC
inhibitor Ro31-8220 (Goldsmith and Gnegy, unpub-
lished observation). This suggests that a 15 min treat-
ment with TPA is inducing PKC to phosphorylate
GAP-43 in SK-N-SH cells and the same pattern is
maintained throughout the 72 h. Because the 21 kDa
fragment also had an increased phosphate content,
PKC could be activating another protein kinase
which phosphorylates GAP-43. The 21 kDa frag-
ment is the correct size for amino acids 133^226
and may contain a non-PKC-phosphorylated site.
This fragment contains potential phosphorylation
sites for a proline-directed kinase at threonine172
[48] and casein kinase II at serine191=192 [41]. The
control sample did not show the presence of a 15
kDa fragment after SAPV8 treatment likely due to
the substantially lower amount of radioactivity in
this sample. The PKC site might not be substantially
phosphorylated in control, untreated cells. Regard-
less, based on the similarity of digestion patterns
for all three TPA treatments, we conclude that
GAP-43 is being phosphorylated at the same site(s),
independent of the length of treatment with TPA.
Similarly, the phosphopeptide patterns from tryp-
sin-digested MARCKS were similar whether the cells
were treated with TPA for 15 min, 17 or 72 h. The
enhanced phosphorylation on two MARCKS frag-
ments (peaks at fractions 40 and 50) in TPA-treated
cells compared to untreated cells could re£ect phos-
phorylation by PKC at both sites or it could re£ect
phosphorylation by another kinase that is activated
by PKC. TPA-induced phosphorylation by PKC can
activate MAP kinase in SH-SY5Y cells [36]. Re-
cently, p42 MAP kinase has been shown to phos-
phorylate MARCKS at ser113 in vitro [45].
MARCKS is a substrate for at least two other types
of protein kinases, proline-directed kinases [51,53]
and PKC-related kinase-1 (PRK1), which phosphor-
ylates MARCKS at the same sites as PKC [37]. It is
not known whether PRK1 can be activated by PKC.
In summary, we report a maintenance of phos-
phorylation of MARCKS and GAP-43 in SK-N-
SH cells after long-term TPA treatment. Our results
would suggest that MARCKS and GAP-43 can be
phosphorylated by PKC isozymes that remain active
in membrane fractions during the continuous TPA.
Enhanced GAP-43 synthesis, however, in response to
72 h of TPA appeared to balance out the elevation in
32P-incorporation. Therefore, prolonged PKC stimu-
lation may maintain phosphorylation of some sub-
strates depending on their subcellular location, the
type of PKC isozymes and perhaps the metabolism
of TPA itself.
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